QTQi-Qun Tang

Qi-Qun Tang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qi-Qun Tang has a total of 581 co-authors. Here are the top co-authors by number of shared publications:

  • Shu-Wen Qian

    Key Laboratory of Metabolism and Molecular Medicine of the Ministry of Education, Department of Biochemistry and Molecular Biology of School of Basic Medical Sciences and Department of Endocrinology and Metabolism of Zhongshan Hospital, Fudan University; Shanghai 200032, China

    26 shared publications
  • Yang Liu

    Key Laboratory of Metabolism and Molecular Medicine of the Ministry of Education, Department of Biochemistry and Molecular Biology of School of Basic Medical Sciences and Department of Endocrinology and Metabolism of Zhongshan Hospital, Fudan University; Shanghai 200032, China

    25 shared publications
  • Yan Tang

    Key Laboratory of Metabolism and Molecular Medicine of the Ministry of Education, Department of Biochemistry and Molecular Biology of School of Basic Medical Sciences and Department of Endocrinology and Metabolism of Zhongshan Hospital, Fudan University; Shanghai 200032, China

    19 shared publications
  • Liang Guo

    Key Laboratory of Metabolism and Molecular Medicine of the Ministry of Education,Department of Biochemistry and Molecular Biology of School of Basic Medical Sciences and Department of Endocrinology and Metabolism of Zhongshan Hospital,Fudan University,Shanghai,China

    18 shared publications
  • Xi Li

    Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, and Department of Biochemistry and Molecular Biology, Fudan University Shanghai Medical College

    17 shared publications
  • Hai-Yan Huang

    Key Laboratory of Metabolism and Molecular Medicine, the Ministry of Education, Department of Biochemistry and Molecular Biology, Fudan University Shanghai Medical College, Shanghai 200032, China

    14 shared publications

Latest Publications

  • Open Access

    Adipose GPD2 Couples Glycolytic Signals to Epigenetic Control of Metabolic Homeostasis

    by Yi-Jie Shi, Meng Ding, Lin-Xi Xiao, Ge Zhang, Xin Dou, Hong-Yu Xu, Yi-Fan Xia, Yi-Fan Ke, Ze-Yi Man, Jin-Yi Xia, et al.

    The glycerol-3-phosphate shuttle (G3PS) is a classic reducing equivalent transferring system, yet its role in adipose metabolism remains poorly understood. Here, we identify mitochondrial glycerol-3-phosphate dehydrogenase (GPD2), the core enzyme of G3PS, as a critical orchestrator of adipose thermogenesis and systemic metabolic homeostasis. Adipocyte-specific GPD2 knockout mice exhibited impaired thermogenic capacity and energy expenditure, rendering them susceptible to obesity and metabolic dysfunction. Mechanistically, GPD2 deficiency elevated cytosolic NADH, which suppressed glycolysis and decreased the levels of key metabolites, such as acetyl-CoA, thereby diminishing H3K27ac at thermogenic gene loci and silencing these genes. NADH depletion with an NADH oxidase rescued both glycolysis and thermogenic gene expression. In support of this mechanism, we defined a previously undescribed enhancer of Ucp1 whose H3K27ac was tightly controlled by GPD2. Remarkably, replenishing the acetyl-CoA pool or directly restoring H3K27ac at the Ucp1 enhancer reversed UCP1 expression in GPD2-deficient adipocytes. Importantly, we find that human adipose GPD2 expression is inversely correlated with BMI, WHR, and HOMA-IR, underscoring its clinical relevance. Collectively, our findings establish GPD2 as an essential node in the metabolic-epigenetic axis that governs thermogenic activation and energy balance.

  • Open Access

    Deleting Bmp4 in brown fat unlocks an arachidonic acid-AMPK axis to boost energy expenditure

    by Yan-Jue Song, Ting Meng, Zhen-Yu Xu, Ting Zhang, Zhao-Ning Wang, Dai-Chen Yao, Li-Jie Yang, Ping Wu, Shu-Wen Qian, Yang Liu, et al.


  • Open Access

    Three-dimensional mapping and functional analysis of sympathetic innervation in aortic perivascular adipose tissue

    by Zhao-Ning Wang, Yan-Jue Song, Liang Tan, Zhen-Yu Xu, Ting Meng, Dai-Chen Yao, Yang Liu, Shu-Wen Qian, Qi-Qun Tang, Yan Tang

    Perivascular adipose tissue (PVAT) is a critical regulator of vascular homeostasis, and sympathetic nerves play a fundamental role in vascular function. However, the function of PVAT as an intermediary in neurovascular communication remains poorly understood. Due to the limitations of conventional two-dimensional (2D) imaging and the low tyrosine hydroxylase signal observed at room temperature, we reevaluated the sympathetic neuroanatomy of aortic PVAT (aPVAT) using volume fluorescence imaging under cold conditions. This approach enabled whole-mount three-dimensional (3D) visualization of the sympathetic network in murine aPVAT. Retrograde tracing was performed to identify neural origins. Cold-exposed mice were assessed for sympathetic activity, plasma norepinephrine levels, and blood pressure fluctuations. The function of aPVAT sympathetic nerves was further examined via local ablation with 6-hydroxydopamine. Our results revealed an undescribed, hierarchically organized sympathetic network, characterized by a primary nerve trunk along the aortic arch that branches into secondary fibers penetrating into the adipose tissue. This innervation exhibited a significant increase in density under cold exposure. Retrograde tracing confirmed the left stellate ganglion as the predominant source, which was shared by major thoracic organs such as the heart and lung. Importantly, local ablation of sympathetic nerves within aPVAT abolished the cold-induced hypertensive response, while ablation of sympathetic nerves within inguinal white adipose tissue had no such effect on hypertension. These findings established sympathetic nerves within aPVAT as a critical source of perivascular innervation and identified this localized neuro-adipovascular circuit as a potential therapeutic target for neurogenic hypertension.

  • Open Access

    Palmitoleic acid promoted by BMPR2 signaling primes CD169 macrophages and alleviates liver fibrosis

    by Hong Ma, Jinkun Zhong, Qilin Peng, Mengyuan Dai, Linyuan Wang, Jianan Wang, Danchun Huang, Yang Liu, Yan Tang, Wei Xu, et al.

    Bone morphogenetic proteins (BMPs) participate in the energy metabolism. BMP receptor type 2 (BMPR2) is expressed in the liver. Whether BMPR2 is involved in the pathophysiology of nonalcoholic fatty liver disease (NAFLD) has not been studied. In this study, we analyzed the RNA-sequence data of several patient cohorts and found that BMPR2 expression decreases at the stages of advanced fibrosis. A mouse model featuring BMPR2 knockout demonstrate that BMPR2 knockout in the liver produces profibrotic effect upon long-term high-fat and high-fructose (HFF) diet challenge. BMP signaling promotes biosynthesis of unsaturated fatty acids, which is repressed under BMPR2 knockout condition. The most affected unsaturated fatty acid, palmitoleic acid (POA), is found to activate CD169 macrophages. Moreover, CD169 macrophages is revealed to have high levels of lysosomal enzyme along with matrix metalloproteinase 8, which degrades collagen and alleviates fibrosis. Our study demonstrates that BMPR2 influences over the progression of liver fibrosis induced by the HFF diet through fatty acid-regulated CD169 macrophages. POA-primed macrophages might be a potential therapeutic strategy for the treatment of liver fibrosis.


  • The X-Age Project to construct a Chinese aging clock

    by Jiaming Li, Mengmeng Jiang, Qiaoran Wang, Zikai Zheng, Jianghua Shen, Jingyi Li, Muzhao Xiong, Yandong Zheng, Xiaoyong Lu, Yusheng Cai, et al.

    The global surge in the population of people 60 years and older, including that in China, challenges healthcare systems with rising age‐related diseases. To address this demographic change, the Aging Biomarker Consortium (ABC) has launched the X-Age Project to develop a comprehensive aging evaluation system tailored to the Chinese population. Our goal is to identify robust biomarkers and construct composite aging clocks that capture biological age, defined as an individual’s physiological and molecular state, across diverse Chinese cohorts. This Perspective outlines the core objectives, methodological framework and key deliverables of the X-Age Project, including cohort recruitment, standardized sample collection, multimodal data acquisition and clock model development. By integrating interdisciplinary expertise, we aim to provide a practical and scalable platform for understanding aging complexity and heterogeneity, early detection of accelerated aging and evaluation of aging interventions.


  • Open Access

    Hepatic ASPG-mediated lysophosphatidylinositol catabolism impairs insulin signal transduction

    by Feiyan Li, Hua-Sheng Huang, Qingwen Zhao, Wei Zhang, Ting Shi, Wenjing Lv, Qi Zhu, Haojie Liu, Yingjiang Xu, Haiyan Huang, et al.

    Bioactive glycerolysophospholipids (GLPs) are implicated in the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity; however, the mechanisms underlying glycerolysophospholipid-mediated changes in insulin signaling remain poorly understood. Here, we identify the amino acid-metabolism enzyme asparaginase (ASPG) as a critical regulator of systemic fatty acid handling and insulin signal transduction. Hepatic ASPG expression levels negatively correlate with insulin sensitivity in humans. Loss of Aspg in MASLD mice modifies the liver hepatokine secretome, enhancing systemic insulin sensitivity. Notably, ASPG bears lysophospholipase activity towards the bioactive lipid lysophosphatidylinositol (LPI) in vitro and in vivo. Mechanistically, Aspg deficiency results in accumulation of intracellular LPIs and consequently in suppression of tyrosine phosphatase PTP1B activity. This in turn decreases FOXO1-dependent expression of the hepatokine Sepp1 , leading to reduced SEPP1 secretion and extrahepatic insulin-sensitization. In summary, this study uncovers a novel biological mechanism whereby ASPG-controlled bioactive lipid levels modulate insulin resistance and insulin secretion, suggesting complementary therapeutic strategies for the improvement of systemic glucose homeostasis.


  • Open Access

    Obesity hinders the efficacy of adipose-derived stem cells for knee osteoarthritis by reducing the proportion of DPP4+ stem cells

    by Yan Tang, Zhen-Yu Xu, Sai-Sai Song, Yan-Jue Song, Li-Jie Yang, Lei Wang, Yang Liu, Shu-Wen Qian, Zhi-Ying Pang, Qi-Qun Tang, et al.

    Osteoarthritis (OA) is the most prevalent and disabling joint disease, while adipose-derived stem cells (ASCs) have emerged as a promising therapeutic option in pre-clinical studies. However, the therapeutic efficacy of ASCs may be influenced by the source of these cells, especially in obese patients. This study compared the effects of intra-articular injections of ASCs from wild-type (WT) and ob/ob (OB) mice. Behavioral and histological analyses demonstrated that WT-ASCs significantly alleviated OA symptoms, restoring paw withdrawal thresholds and improving gait parameters while reducing cartilage degradation. In contrast, OB-ASCs only partially improved gait and did not significantly affect cartilage degeneration. Single-cell RNA sequencing of stromal vascular fractions from subcutaneous adipose tissue revealed distinct ASC subpopulations, with DPP4+ cells being notably reduced in obese mice. In vitro, OB-ASCs and high-fat-diet (HFD)-ASCs exhibited impaired proliferation and chondrogenesis but HFD-ASCs retained anti-inflammatory properties. Further investigation using fluorescence-activated cell sorting (FACS) isolated DPP4+ and DPP4− ASCs from WT mice, demonstrating that DPP4+cells had superior chondrogenic potential and reduced OA pain more effectively than DPP4− cells. These findings suggest that obesity impairs the therapeutic potential of ASCs in OA, primarily due to reduced proliferation and chondrogenesis, and highlight DPP4+ ASCs as a promising candidate for cell therapy in OA.


  • Open Access

    A framework of biomarkers for adipose tissue aging: a consensus statement by the Aging Biomarker Consortium

    by Jian Yu, Yankang Zhang, Ting Zhang, Yan Bi, Yan Chen, Zheng Chen, Zhe Dai, Feifan Guo, Lixin Guo, Cheng Hu, et al.

    Adipose tissue serves as a crucial energy storage and metabolic organ in the human body. With the surging of elderly population in China comes significant challenges in preventing and managing age-associated diseases, while adipose tissue aging represents one of the pivotal initiating events for multi-organ senescence. To address these challenges, the Aging China Biomarkers Consortium (ABC) has established an expert consensus on biomarkers of adipose tissue aging by digesting literature and collecting insights from scientists and clinicians. This consensus provides a comprehensive evaluation of the key changes and characteristics, as well as biomarkers related to adipose tissue aging and proposes a systematic framework categorizing these biomarkers into functional, structural and humoral dimensions. Within each dimension, the ABC recommends clinically and empirically validated biomarkers and parameters for assessing both physiological and pathological changes in adipose tissue during aging, which aims to establish a foundation for future prediction, diagnosis, early warning and treatment for adipose tissue aging and its related diseases, with the ultimate goal of improving adipose tissue health and promoting healthy aging in elderly populations both in China and worldwide.


  • Open Access

    The brown fat-enriched exosomal miR-206-3p attenuates hepatic lipogenesis by decreasing pentose phosphate pathway

    by Li-Jie Yang, Qiu-Kai Tang, Lei Wang, Yan-Jue Song, Zhen-Yu Xu, Xi-Ni Ma, Yang Liu, Shu-Wen Qian, Qi-Qun Tang, Yan Tang

    Brown adipose tissue (BAT) orchestrates interorgan crosstalk through secreted mediators, including proteins, lipids, and exosomal microRNAs (miRNAs). However, the precise molecular identities and functional contributions of these mediators remain elusive. In this study, we isolated exosomes from BAT and conducted miRNA sequencing, identifying miR-206-3p as a previously unrecognized exosomal miRNA with the potential to alleviate metabolic dysfunction-associated fatty liver disease (MAFLD). In vivo, adipose-specific knockout of miR-206-3p in mice exacerbated obesity-induced MAFLD, glucose intolerance, insulin resistance, and impaired energy expenditure. Mechanistically, BAT-derived miR-206-3p is selectively packaged into exosomes via a BAT-specific “exo motif” and transported to the liver, where it targets the 3′ untranslated regions (3′-UTRs) of glucose-6-phosphate dehydrogenase (G6pd) and transketolase (Tkt), which are key enzymes in the pentose phosphate pathway (PPP). The PPP generates nicotinamide adenine dinucleotide phosphate (NADPH) and ribulose-5-phosphate (Ru-5-P) to support lipogenesis and nucleotide synthesis. miR-206-3p modulates these processes by decreasing NADPH production to inhibit hepatic lipid synthesis and increasing Ru-5-P availability to promote cell proliferation. Notably, obese individuals exhibit reduced serum exosomal miR-206-3p alongside upregulated hepatic PPP enzymes. Our study reveals that BAT-derived exosomal miR-206-3p serves as a mediator of BAT−liver crosstalk, suggesting its potential as a therapeutic target for obesity-related disorders, particularly MAFLD.


  • Open Access

    Non-catalytic mechanisms of KMT5C regulating hepatic gluconeogenesis

    by Qingwen Zhao, Xuan Cui, Qi Zhu, Feiyan Li, Ran Bao, Ting Shi, Haojie Liu, Wenjing Lv, Yingjiang Xu, Yue Gao, et al.

    Lysine methyltransferase KMT5C catalyzes deposition of trimethylation on histone H4 lysine 20 (H4K20me3), an epigenetic marker usually associated with gene repression and maintenance of heterochromatin. KMT5C is widely expressed in a variety of tissues, however, its functional role in liver has not been explored. Here, we show Kmt5c is a fasting- and glucagon-induced gene in liver which regulates hepatic gluconeogenesis. Loss of KMT5C in hepatocytes results in downregulated gluconeogenic gene expression and compromised glucose output during fasting. KMT5C fosters gluconeogenesis through decreasing ubiquitination-mediated PGC-1α degradation, which is unexpectedly independent of its methyltransferase activity. In fact, KMT5C impedes the E3 ligase RNF34 binding to the C-terminal of PGC-1α and subsequent ubiquitination-associated degradation. The diabetic mice models and patients show elevated KMT5C levels in the livers, and KMT5C knockdown beneficially reduces gluconeogenesis and fasting blood glucose levels. In conclusion, the present study identifies KMT5C as a hepatic gluconeogenesis regulator by affecting PGC-1α stability.